RE:RE:RE:RE:Encouraging This is as close as having the proof they have proof of concept for TH19P01. Why would you start the search to hire a RNA specialist if you are not sure your peptide conjugate works at entering cells by binding to sortilin? It is not 100% sure they have the proof of concept, but it is close. Add that to the feedback from the management's meetings with big investors. It also shows a willingness to develop full proprietary PDCs in the future. RNA sequences that can be used as siRNA are easy to identify. What is hard is to get them inside the cells intact and free.
Wino115 wrote: Would they bother hiring scientist at the cutting edge around ways to possibly kill tumor cells if they weren't extremely confident of the POC signs they've seen so far. I just don't think they would. To me, it's one more positive around the concept showing that it works. As for efficacy, we'll have to see, but it seems to have moved from conceptual invivo to human proof at least around the peptide, targeting, internalization part. All good.